Overview of anticoagulant drugs for the future

This publication has 93 references indexed in Scilit:

• Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
  Critical Care Medicine, 2001
• Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
  New England Journal of Medicine, 2001
• Role of Zymogen and Activated Factor X as Scaffolds for the Inhibition of the Blood Coagulation Factor VIIa-Tissue Factor Complex by Recombinant Nematode Anticoagulant Protein c2
  Published by Elsevier ,2001
• Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries.
  Circulation, 2001
• Thrombin-mediated Feedback Activation of Factor XI on the Activated Platelet Surface Is Preferred over Contact Activation by Factor XIIa or Factor XIa
  Published by Elsevier ,2000
• Effect of locally-applied active site-blocked activated factor VII (ASIS) on experimental arterial thrombosis
  Blood Coagulation & Fibrinolysis, 2000
• Local Inhibition of Tissue Factor Reduces the Thrombogenicity of Disrupted Human Atherosclerotic Plaques
  Circulation, 1999
• Oral Delivery of Anticoagulant Doses of Heparin
  Circulation, 1998
• Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model
  Blood, 1993
• Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.
  Journal of Clinical Investigation, 1991